{"filings":[{"id":1580396,"accession_number":"0001185185-26-002886","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2026-07-10T20:00:56+00:00","items":["1.01","9.01"],"status":"ready","headline":"Z Squared amends Skycore Digital LOI: extends deadline, drops break-up fee, ends exclusivity","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Drop dead date extended from June 30, 2026 to January 15, 2027.","$500,000 break-up fee payable by Z Squared eliminated entirely.","Exclusivity provisions terminated; discussions now non-exclusive.","LOI now explicitly non-binding except for confidentiality, governing law, dispute resolution.","No assurance definitive documentation will be executed or acquisition consummated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1501077,"accession_number":"0001185185-26-002828","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2026-07-07T21:08:43+00:00","items":["1.01","9.01"],"status":"ready","headline":"Z Squared enters $300M at-the-market equity offering with Roth Capital Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Sales Agreement with Roth Capital Partners for at-the-market offering of up to $300M of common stock.","Agent commission of 3.0% of gross sales price; Company may also sell shares directly to Agent as principal.","Sales may be made on Nasdaq or in negotiated transactions at prevailing market prices.","Agreement may be terminated by either party on five days' notice; automatically terminates upon sale of all Placement Shares.","Legal opinion from Zarif Law Group P.C. filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1362956,"accession_number":"0001185185-26-002750","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2026-06-30T21:20:40+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Z Squared appoints Jeffery Harris as CTO; discloses LOI to acquire Paradox Data","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffery Harris appointed CTO effective June 24, 2026; annual base salary $225,000 plus RSU bonus of $675,000 and option for 100,000 shares.","Harris is founder and CTO of Paradox Data LLC, which Z Squared has a binding LOI to acquire for $5M in Series D preferred stock.","Acquisition subject to definitive docs, due diligence, and Nasdaq stockholder approval; drop-dead date July 31, 2026.","Harris's background includes military aerospace electronics and leadership at Paradox Data, Paradox Infrastructure, and Xero Labs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1335638,"accession_number":"0001185185-26-002708","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2026-06-29T21:19:05+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Z Squared raises $15.4M equity via SEPA completion, added to Russell 2000/3000","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised approx $15.3M ($15.4M gross) from sale of 1,302,806 shares at $11.84 to YA II PN under SEPA; no new debt.","Proceeds to support AI infrastructure acquisition and conversion; Phase 1 target of 100 MW AI-ready capacity.","Formally added to Russell 3000 and Russell 2000 indexes effective June 26, 2026.","Signed LOIs to acquire Skycore Digital (~24 MW with path to 42 MW) and majority interest in Paradox Data LLC.","Maintains virtually no corporate debt; all-equity financing preserves balance sheet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1285441,"accession_number":"0001185185-26-002659","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2026-06-25T22:57:08+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Z Squared signs binding LOI to acquire majority interest in Paradox Data for $5M in Series D Preferred","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition targets Paradox Data, operator of Union County Campus in El Dorado, AR, with up to 150 MW firm power.","Consideration entirely in Series D Convertible Preferred Stock with $5M aggregate liquidation preference; no cash or debt.","Paradox's assets include ~8 MW energized power, 10-acre land parcel, and immersion-cooling technology.","Post-closing milestone: pursue interconnection request for up to 50 MW of utility power.","Closing expected by July 31, 2026, subject to due diligence, consents, and potential Nasdaq stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":860756,"accession_number":"0001683168-26-004560","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2026-06-04T20:02:30+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Z Squared Enters $50M Equity Forward Agreement with LucentHash; LOI to Acquire Skycore Digital (42 MW)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered $50M committed equity forward purchase agreement with LucentHash / Data Part Capital; shares issued at 95% of 5-day VWAP.","Each draw between $50K and $5M; 14-day minimum between draws; 9-month lock-up; floor price $5 (reset to $3 after three floor cancellations).","Commitment fee of $500K (1%) paid in shares over first five draws; capped at 19.99% of outstanding unless shareholder approval obtained.","Signed binding LOI to acquire Skycore Digital: three NC sites powered by Duke Energy with 42 MW total capacity (18 MW available now).","Company controls draw timing; purchaser prohibited from short-selling or hedging ZSQR common stock during commitment period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":778924,"accession_number":"0001683168-26-004425","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K/A","filed_at":"2026-06-01T20:30:28+00:00","items":["9.01"],"status":"ready","headline":"Z Squared OpCo reports $323K net loss for 2025, no revenue, going concern","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Net loss of $323 for year ended Dec 31, 2025 vs $60 in 2024; no revenues generated.","Cash and cash equivalents of $1,402 at Dec 31, 2025; total assets $1,402.","Accumulated deficit of $443; auditor expresses substantial doubt about going concern.","Capital contribution of $1,725 received in 2025; $120 advance from affiliate remains.","Pre-revenue crypto miner planned to acquire ~9,000 mining machines via asset-for-share exchange, contingent on merger close and SEC court order."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":611520,"accession_number":"0001683168-26-004273","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2026-05-22T21:00:14+00:00","items":["5.02"],"status":"ready","headline":"Z Squared Co-CEO Michelle Burke resigns; David Halabu becomes sole CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michelle Burke resigned as Co-CEO and director on May 22, 2026; no disagreement cited.","David Halabu, previously Co-CEO since April 24, 2026, becomes sole CEO effective same date.","Burke returns to Minting Dome, Inc.; Master Services Agreement remains in effect.","Board has not yet appointed a successor for Burke's board vacancy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":563127,"accession_number":"0001683168-26-004194","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2026-05-20T23:56:08+00:00","items":["7.01","9.01"],"status":"ready","headline":"Z Squared outlines Phase 1 plan to reach 100 MW AI-ready capacity; signs binding LOI for Skycore acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 goal: 100 MW of AI-ready capacity over 18 months across multiple U.S. sites.","Signed binding LOI to acquire Skycore Digital (North Carolina sites) with up to 42 MW potential capacity.","Skycore has 24 MW energized capacity plus 18 MW via Duke Energy Letters of Authorization.","Company virtually debt-free after April 2026 Nasdaq listing; evaluating additional acquisition targets.","Strategy: acquire operating sites with existing power and convert to AI inference infrastructure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95250,"accession_number":"0001683168-26-003426","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Z Squared to acquire Skycore Digital for up to $22M in Series B Preferred; new CEO and board installed","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Binding LOI to acquire 100% of Skycore Digital; consideration up to $22M in Series B Preferred with 8% dividend.","All prior directors and officers resigned; David Halabu and Michelle Burke appointed Co-CEOs, Brian Cogley CFO, Ryan Schadel CMO.","New board includes Adam Sohn, Bryan Fuerst, Kenneth Cooper; Audit, Compensation, and Nominating committees formed.","Issued 200K shares to Wasserman, up to 566K to MAP, $100K value to MZHCI, $75K to Retail Sparks in unregistered sales.","Halabu granted options for 500K shares, Cogley and Schadel each 100K; Cogley $250K RSU bonus, Schadel $150K RSU bonus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95249,"accession_number":"0001683168-26-003388","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.01","5.01","5.02","5.03","9.01"],"status":"ready","headline":"Coeptis reverse-merger closes; becomes Z Squared crypto miner; ticker now ZSQR","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed April 24, 2026; former Coeptis biopharma assets distributed pre-close as dividend to CHI.","Z Squared stockholders received 43,877,497 Coeptis shares (~85% of post-merger equity); control shifted.","New board of five, CEO David Halabu, COO Michelle Burke, CFO Brian Cogley; prior directors/officers resigned.","OpCo mines DOGE and LTC with 9,800 machines (L7, L9, DG1+); valuation ~$660M as of Jan 2025.","Energy cost fixed at $0.088/kWh; mined assets converted to fiat within two weeks to limit volatility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95248,"accession_number":"0001683168-26-003247","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Z Squared completes pro rata distribution of Coeptis Holdings shares and starts trading under ZSQR","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Pro rata distribution of Coeptis Holdings, Inc. common stock to shareholders of record on January 2, 2026.","Each shareholder receives one share of Coeptis Holdings common stock for each share held.","Distribution effected on April 27, 2026.","Common stock begins trading on Nasdaq Global Market under ticker ZSQR on April 27, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95247,"accession_number":"0001683168-26-003199","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Coeptis completes reverse merger with Z Squared; shares to trade as ZSQR April 27","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Coeptis Therapeutics completes business combination with computing infrastructure firm Z Squared Inc.","Combined entity renamed Z Squared Inc.; shares to trade on Nasdaq Global Market under ZSQR starting April 27, 2026.","Prior to close, Coeptis distributed its biopharmaceutical business to its stockholders via pro rata distribution.","Post-merger: ~51.5M shares outstanding; former Z Squared stockholders own ~85%, legacy Coeptis holders own ~15%.","Z Squared COO cites vertically integrated platform across three states with dynamic power management and hardware lifecycle program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95246,"accession_number":"0001683168-26-002726","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2026-04-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nasdaq approves listing of post-merger Coeptis/Z Squared stock under ticker ZSQR","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Nasdaq approved listing of post-merger common stock on the Global Market under symbol ZSQR, subject to merger closing.","Approval satisfies a key closing condition in the proposed merger between Coeptis and Z Squared Inc.","Merger expected to close in Q2 2026; Z Squared to become wholly owned subsidiary, renamed Z Squared Inc.","Other conditions already met: Form S-4 effective and shareholder approval obtained on Jan 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108168,"accession_number":"0001683168-26-000963","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Coeptis regains Nasdaq listing compliance; officers exchange underwater options for restricted stock","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Coeptis on Feb 9, 2026 that it regained compliance with annual meeting requirement for continued listing on Nasdaq Capital Market.","Option repricing/exchange program approved; officers surrendered underwater options for restricted stock, e.g., CEO Mehalick received 51,250 restricted shares.","Officers also exercised retained options: CEO Mehalick exercised options for 148,875 shares; other officers exercised smaller amounts.","All options with exercise prices above current FMV were accelerated to fully vested; program approved by stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108167,"accession_number":"0001683168-26-000751","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Coeptis stockholders approve merger with Z Squared (94% FOR), name change, spinout, new board","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["3,472,303 shares voted FOR Merger Proposal (94.0% of votes cast); 225,250 AGAINST; merger with Z Squared approved.","Name change to 'Z Squared Inc.' approved: 3,471,316 FOR, 226,240 AGAINST.","Spin-out of biopharm operations (excluding GEAR) approved: 3,470,423 FOR, 225,865 AGAINST.","Board of combined company elected: Bryan Fuerst, Adam Sohn, David Halabu, Michelle Burke, Kenneth Cooper.","New equity incentive plan approved: 3,681,614 FOR; option repricing approved: 3,453,849 FOR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108166,"accession_number":"0001683168-26-000370","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Coeptis Therapeutics receives Nasdaq delisting notice for missing annual meeting; meeting set for Jan 30","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq letter on Jan 12, 2026 cites violation of Listing Rules 5620(a) and 5810(c)(2)(G) for failing to hold annual meeting within 12 months of fiscal year end (Dec 31, 2024).","Company has 45 days to submit compliance plan; if accepted, Nasdaq may grant exception until June 29, 2026.","Annual meeting scheduled for January 30, 2026, which Coeptis believes will cure the deficiency.","Ticker: COEP (Nasdaq); warrants trade as COEPW."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159075,"accession_number":"0001683168-25-002856","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Coeptis Therapeutics to merge with Dogecoin miner Z Squared; biopharma spun out","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Coeptis to spin out biopharma; Z Squared becomes wholly-owned subsidiary focused on Dogecoin mining.","Z Squared shareholders receive Coeptis equity for 9,000 DOGE mining machines; minimum asset value of $660.3M required.","Post-close leadership: Z Squared CEO David Halabu becomes CEO; Michelle Burke COO; Dave Mehalick exits board.","Closing expected Q3 2025; conditions include shareholder and regulatory approvals and Nasdaq listing.","Combined company to rebrand as Z Squared, aiming to be largest U.S. publicly-traded Dogecoin miner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177522,"accession_number":"0001683168-25-001940","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Coeptis CSO/CMO Colleen Delaney resigns effective March 24; will consult up to 6 months","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Colleen Delaney resigned as Chief Scientific and Medical Officer, effective March 24, 2025.","She joined in August 2023 and is leaving to pursue another business opportunity.","Delaney will provide transition consulting services for up to six months.","No successor has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177521,"accession_number":"0001683168-25-000537","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Coeptis raises $1.1M convertible note and completes $10M Series A preferred stock sale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$1.1M convertible note to Yorkville with 8% interest, maturity Dec 31, 2025; conversion price with floor at $1.00.","Series A preferred stock sale raises ~$10M from accredited investors at $1,000 per share.","Preferred investors receive 13.91% non-voting equity in subsidiaries SNAP Biosciences and GEAR Therapeutics.","Board member Christopher Calise participated in the Series A offering.","Note includes amortization events triggering monthly payments of $250k principal plus 5% premium."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177520,"accession_number":"0001683168-25-000482","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Coeptis regains Nasdaq bid price compliance; delisting risk resolved","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Coeptis on Jan 21, 2025 that it regained compliance with Listing Rule 5550(a)(2).","Company had been below $1.00 bid price for 30 consecutive business days, triggering non-compliance.","CEO Dave Mehalick called the start of a 'transformative year' for Coeptis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194241,"accession_number":"0001683168-24-009012","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2024-12-27T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Coeptis Therapeutics proceeds with 1-for-20 reverse stock split; effective after Dec 30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio set at 1-for-20; effective after market close Dec 30, post-split trading begins Dec 31.","No fractional shares issued; fractional holdings rounded up to whole share.","Split intended to help meet Nasdaq $1.00 minimum bid price requirement.","Stockholder ownership percentage unchanged except for fractional rounding adjustments.","CUSIP changes to 19207A 207; par value remains $0.0001."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194240,"accession_number":"0001683168-24-008891","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Coeptis shareholders elect 7 directors, approve reverse split and $20M equity issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 7 director nominees elected with ~21M votes each; broker non-votes ~9.9M.","Ratified Astra Audit & Advisory as independent auditor for FY 2023: 30.99M for, 1.09M against.","Approved amendment to authorize reverse stock split: 29.40M for, 2.45M against.","Approved issuance of up to $20M securities under Standby Equity Purchase Agreement: 20.76M for.","Advisory vote on executive compensation approved: 20.76M for, 1.24M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194239,"accession_number":"0001683168-24-008765","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Coeptis launches Tech division, signs LOI for data-security asset buy with 10,000 customers","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["New division Coeptis Technologies created; binding LOI to acquire Data Placement Manager and Sensitive Content Manager solutions.","Target risk-mitigation software company serves 10,000 customers across 100+ countries; CEO will join Coeptis management team.","Acquisition expected to close in early 2025, subject to definitive agreements and approvals.","Expansion follows planned NexGenAI Affiliates Network acquisition; Coeptis diversifies into data-security and AI sectors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194238,"accession_number":"0001683168-24-008519","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Coeptis Therapeutics signs binding LOI to acquire NexGenAI AI marketing platform","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Binding letter of intent to acquire NexGenAI Affiliates Network, an AI-powered marketing and RPA platform.","Platform targets biotech, pharmaceutical, and multi-level marketing industries for compliance and efficiency.","Closing subject to preparation and execution of definitive documents; no material terms disclosed.","Acquisition expands Coeptis beyond cell therapy into AI-driven marketing software solutions.","CEO Dave Mehalick says integration will drive operational efficiency and growth opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194237,"accession_number":"0001683168-24-007685","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Coeptis Therapeutics enters $20M SEPA with Yorkville, gets $1.3M convertible note","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $20M of common stock may be sold to Yorkville at 95% of lowest daily VWAP over 3 days.","Convertible promissory note of $1,304,758 issued, bearing 8% interest, matures Nov 1, 2025.","Note conversion price: lower of $1.00 or 95% of lowest 5-day VWAP (floor $0.04).","Commitment fee of $200,000; $80,000 paid in 400,000 shares, $120,000 later in cash or advance.","Proceeds from SEPA sales to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210568,"accession_number":"0001683168-24-006763","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Coeptis Therapeutics replaces auditor; prior reports included going concern qualification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Turner, Stone & Company as auditor; engaged Astra Audit & Advisory, LLC effective immediately for FY 2024.","Turner's audit reports for FY 2022 and 2023 contained a 'going concern' explanatory paragraph but no adverse opinions or disagreements.","No disagreements or reportable events between Coeptis and Turner during the past two fiscal years and subsequent interim periods.","Coeptis provided Turner with disclosures and requested a letter to the SEC; Turner's letter is filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210567,"accession_number":"0001683168-24-006521","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Coeptis Therapeutics gets Nasdaq extension to Jan 15, 2025 to regain $1 bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq Hearings Panel granted continued listing through Jan 15, 2025, subject to compliance with Minimum Bid Price Requirement.","Company plans to implement a reverse stock split to regain compliance.","Original non-compliance notice received Jan 29, 2024; previous compliance period ended July 29, 2024.","CEO Dave Mehalick expressed optimism about regaining and maintaining Nasdaq listing.","Extension follows a hearing on Sep 12, 2024; company had appealed earlier delisting determination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210566,"accession_number":"0001683168-24-005713","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Coeptis says prior financials from Sep 2023 to Mar 2024 not reliable due to accounting errors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee determined non-reliance on financial statements for Q3 2023, FY 2023, Q1 2024, and related registration statements.","Error: notes receivable misclassified as subscription receivables; balance of subscription receivables satisfied as of Aug 12, 2024.","Company expects to file restated financial statements as soon as practicable.","Previously disclosed material weaknesses; hired full-time CFO in 2023 to improve controls.","Restatement may result in litigation, regulatory action, and reputational damage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210565,"accession_number":"0001683168-24-005183","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Coeptis receives Nasdaq delisting notice for bid price non-compliance; plans to appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Coeptis on July 30, 2024 of delisting for failing to maintain $1.00 minimum bid price.","Company had until July 29, 2024 to regain compliance; did not meet $5M stockholders' equity for extension.","Trading of COEP common stock will be suspended Aug 8 unless a hearing is requested by Aug 6.","Coeptis intends to request a hearing and may pursue a reverse stock split to regain compliance.","No assurance that appeal or reverse split will succeed or that listing will be maintained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228892,"accession_number":"0001683168-24-004361","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["3.02","5.02","8.01","9.01"],"status":"ready","headline":"Coeptis raises $4.3M in Series A Preferred financing; CEO granted 2.4M options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $4.3M via sale of 4,300 shares of Series A Preferred at $1,000/share to accredited investors.","Financing led by CJC Investment Trust (entity of board member Christopher Calise).","Series A convertible at $0.40/share; automatic conversion upon $20M+ fundraising.","CEO David Mehalick granted options for 2.4M shares (fully vested, 10-year term) on June 13.","Investors also received 6.45% non-voting equity in new subsidiaries SNAP Biosciences and GEAR Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247529,"accession_number":"0001683168-24-001672","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Coeptis Therapeutics restates 2022 annual and 2023 quarterly financials; prior reports no longer reliable","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee determined 2022 audited and 2023 quarterly financials are unreliable due to accounting errors.","Unrecorded liability from October 2022 merger must be booked; remaining balance immaterial and payable in 2024.","Reimbursement commitment under a January 2023 research agreement requires restatement for Q1-Q3 2023.","Company will file restated financial statements as soon as practicable.","Previously disclosed material weaknesses in internal controls; new CFO hired to improve processes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247528,"accession_number":"0001683168-24-000615","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"Coeptis receives Nasdaq deficiency notice for minimum bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Coeptis that its common stock closing bid price was below $1.00 for 30 consecutive business days.","Company has 180 calendar days, until July 29, 2024, to regain compliance by closing at $1.00 for 10 consecutive days.","If not cured, a second 180-day extension may be available if other listing standards are met.","Delisting could reduce liquidity, limit capital access, and trigger penny stock rules, per updated risk factors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264991,"accession_number":"0001683168-23-009058","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Coeptis stockholders elect 7 directors, approve 5M share equity plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected with over 18.98M votes for each, under 24K withheld.","Ratification of Turner Stone & Company as auditor: 21.9M for, 1,675 against.","Approval of issuance of shares underlying June/October 2023 warrants: 18.68M for, 182.6K against.","Non-binding advisory vote on named executive officer compensation: 18.54M for, 413K against.","Approval of amendment to 2022 Equity Incentive Plan adding 5M shares: 18.69M for, 134K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.15,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264990,"accession_number":"0001683168-23-008638","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2023-12-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Coeptis Therapeutics posts corporate presentation, no financial details in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company filed an 8-K on Dec 5, 2023, announcing a corporate presentation posted to its website.","Presentation furnished as Exhibit 99.1; its specific content is not summarized in the filing.","No material financial or operational updates were disclosed in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264989,"accession_number":"0001683168-23-007466","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2023-10-27T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Coeptis Therapeutics raises $2M in private placement of stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $2M from sale of 2M shares (or pre-funded warrants) plus class A and B warrants to healthcare investor.","Net proceeds approx. $1.73M after placement agent fees and expenses; Ladenburg Thalmann acted as exclusive placement agent.","Warrants exercise price $1.36 per share; class A term 18 months, class B term 5.5 years, exercisable upon shareholder approval or April 2024.","Existing warrants held by same investor amended to reduce exercise price to $1.36 and align exercise period.","Proceeds to be used for product development and general corporate purposes, including working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264988,"accession_number":"0001683168-23-007115","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2023-10-13T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Coeptis Therapeutics issues 3M shares to two investors for $3M; $500k cash, $2.5M notes due 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 2.4M shares to Biofin Ventures for $2.4M ($400k cash + $2M promissory note due Aug 2024).","Issued 600k shares to AG Bio Life Capital I for $600k ($100k cash + $500k note due Aug 2024).","Notes bear 6% interest (18% on default), payable by Aug 30, 2024; investors may prepay.","If Biofin or AG sell shares before maturity, proceeds from sales must be contributed to the company.","Unregistered issuance dilutes existing shareholders by ~3M shares; only $500k received upfront."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282174,"accession_number":"0001683168-23-006170","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2023-08-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Coeptis receives Nasdaq deficiency notice for MVLS below $35M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Coeptis on Aug 28, 2023 that MVLS has been below $35M for 33 consecutive business days.","Company has 180 calendar days (until Feb 26, 2024) to regain compliance by closing MVLS at $35M+ for 10 consecutive days.","Deficiency notice has no immediate effect on trading of common stock (COEP) or warrants (COEPW).","If compliance is not achieved by Feb 26, 2024, Nasdaq may delist; company may appeal to a hearings panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282173,"accession_number":"0001683168-23-005994","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2023-08-22T23:59:59+00:00","items":["1.01","2.01","8.01","9.01"],"status":"ready","headline":"Coeptis completes exclusive license of Deverra allogeneic NK cell platform and two Phase 1 assets","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Paid ~$570K cash and issued 4M shares to Deverra for exclusive rights to allogeneic stem cell expansion platform.","Acquired two IND applications and Phase 1 trials (NCT04901416, NCT04900454) for NK cell therapy DVX201.","Platform generates off-the-shelf NK and myeloid cells; aligns with Coeptis' SNAP-CAR and GEAR technologies.","Transaction moves Coeptis from pre-clinical to a clinical-stage company with two ongoing Phase 1 studies.","Pipeline includes unmodified NK cells for AML/MDS and viral infections plus engineered NK/MAC candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301304,"accession_number":"0001683168-23-004220","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Coeptis Therapeutics closes $3.5M underwritten offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering gross proceeds ~$3.5M before expenses; closed June 16, 2023 to a single healthcare investor.","Components: 2,150,000 shares, 1,350,000 pre-funded warrants at $0.0001, 3,062,500 Series A and 3,062,500 Series B warrants at $1.65.","Series A and B warrants exercisable for five years starting six months after issuance; fixed pricing with no resets.","Ladenburg Thalmann acted as sole book-running manager; lock-up of 75 days for company and insiders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301303,"accession_number":"0001683168-23-004043","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Coeptis transfers listing from Nasdaq Global Market to Capital Market effective June 13","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq approval on June 8, 2023 to transfer from Global Market to Capital Market.","Trading on Nasdaq Capital Market begins June 13, 2023 under existing symbols COEP and COEPW.","Transfer resolves previously announced continued listing deficiency, which is deemed closed.","Nasdaq Capital Market has similar operational requirements but less stringent financial standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301302,"accession_number":"0001683168-23-003924","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Coeptis Therapeutics provides investor presentation; no material new data in available excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company began using an investor presentation deck on June 5, 2023, furnished as Exhibit 99.1.","Exhibit content is truncated in filing; no specific financial or strategic details can be extracted.","Presentation is furnished under Regulation FD and is not filed or incorporated by reference.","Tickers mentioned: COEP (common stock) and COEPW (warrants)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301301,"accession_number":"0001683168-23-003496","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2023-05-17T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Coeptis Therapeutics appoints Brian Cogley as CFO; Christine Sheehy steps down","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christine Sheehy steps down as CFO effective May 17, 2023; remains VP of Compliance and Corporate Secretary.","Brian Cogley, 37, appointed CFO; has 15 years of accounting/finance experience including Big 4 and life sciences roles.","Cogley's base salary $200,000/year, eligible for annual bonus and stock incentive plan participation.","Cogley previously held senior roles at CFGI, NexTier Bank, Calgon Carbon, TriState Capital, and KPMG."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321147,"accession_number":"0001683168-23-000454","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2023-01-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Coeptis enters sponsored research agreement with Univ. of Pittsburgh for SNAP-CAR HER2 pre-clinical work","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sponsored research agreement with University of Pittsburgh to advance SNAP-CAR T cells targeting HER2-positive cancers.","Pre-clinical work will support IND filing for clinical trials, initially targeting ovarian cancer.","Research led by Dr. Lohmueller and Dr. Deiters; IQVIA to assist as CRO for lead candidate selection.","HER2 overexpressed in ~28% of ovarian cancer and ~25% of breast cancer cases, per the press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339250,"accession_number":"0001683168-22-008676","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2022-12-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Coeptis Therapeutics receives Nasdaq deficiency notice for MVLS below $50M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq letter dated Dec. 22, 2022; MVLS below $50M for 30 consecutive business days.","Company has 180 calendar days, until June 20, 2023, to regain compliance.","If MVLS closes at $50M+ for 10 consecutive business days before deadline, compliance will be achieved.","No immediate effect on listing or trading of COEP common stock or warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339249,"accession_number":"0001683168-22-007257","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.01","5.01","5.02","5.03","5.06","7.01","8.01","9.01","3.02"],"status":"ready","headline":"Coeptis Therapeutics completes reverse merger with Bull Horn Holdings; now Nasdaq-listed","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed Oct 28, 2022; Coeptis becomes wholly-owned subsidiary of Bull Horn (renamed Coeptis Therapeutics Holdings).","Post-merger capital: 19.5M shares outstanding; Coeptis stockholders ~88%, Bull Horn ~12%.","Pre-closing, Coeptis raised $3.27M via Reg A at $3.00/share and $5.25M from warrant exercises at avg $1.40/share.","Pipeline: CD38-GEAR-NK (multiple myeloma), CD38-Diagnostic, and SNAP-CAR-T licensed from Univ. of Pittsburgh.","Board expanded to 7 members; new directors include David Mehalick, Daniel Yerace, Christopher Calise, others."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339248,"accession_number":"0001213900-22-066510","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2022-10-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bull Horn shareholders approve Coeptis merger; 88.5% of public shares redeemed, trust drops to $3.8M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Shareholders approved all proposals: domestication to Delaware, merger with Coeptis, equity plan, charter amendments, and director election.","2,869,654 public shares (88.5% of outstanding) redeemed, leaving approximately $3.8 million in trust from the SPAC.","Post-merger company to be named Coeptis Therapeutics Holdings, Inc.; new board of seven directors elected.","Merger expected to close promptly after satisfaction of remaining conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356629,"accession_number":"0001213900-22-037632","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2022-07-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bull Horn Holdings files investor presentation for merger with Coeptis Therapeutics","summary_kind":"llm","event_type":"m_and_a","confidence":"low","bullets":["SPAC Bull Horn Holdings (BHSE) has a Merger Agreement with Coeptis Therapeutics, dated April 18, 2022.","This 8-K furnishes an investor presentation to be used in connection with the proposed business combination.","No specific financial terms, valuation, or changes were disclosed in the filing or the presentation text provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375076,"accession_number":"0001213900-22-028629","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2022-05-20T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Bull Horn Holdings enters up to $500K working capital note with sponsor","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $500,000 promissory note issued to sponsor Bull Horn Holdings Sponsor LLC for working capital; no interest.","Principal repayable at business combination or winding up; trust account proceeds can be used only after a deal closes.","Sponsor may convert unpaid principal into warrants at $1.00 per warrant, identical to IPO private placement warrants.","Drawdowns in $10,000 increments, maximum $500,000; no prepayment penalty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375075,"accession_number":"0001213900-22-023587","cik":1759186,"company_name":"Z Squared Inc.","ticker":"ZSQR","form_type":"8-K","filed_at":"2022-05-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Bull Horn Holdings issues up to $400K sponsor note to extend business combination deadline to Nov 3, 2022","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Promissory note of up to $400,000 issued to Bull Horn Holdings Sponsor LLC on May 2, 2022.","Note extends initial business combination deadline from May 3, 2022 to November 3, 2022.","Monthly trust account deposits of $66,667 (last $66,665) required to fund extension.","Note is non-interest bearing, repayable upon business combination or liquidation.","Issuance exempt from registration under Section 4(a)(2) of Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":493230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-03T23:59:59+00:00|375075"}